- All sections
- A - Human necessities
- A61P - Specific therapeutic activity of chemical compounds or medicinal preparations
- A61P 31/12 - Antivirals
Patent holdings for IPC class A61P 31/12
Total number of patents in this class: 7638
10-year publication summary
243
|
311
|
267
|
331
|
376
|
461
|
911
|
930
|
599
|
138
|
2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
Principal owners for this class
Owner |
All patents
|
This class
|
---|---|---|
Gilead Sciences, Inc. | 1879 |
127 |
Bristol-myers Squibb Company | 5080 |
89 |
F. Hoffmann-La Roche AG | 7958 |
88 |
The Regents of the University of California | 18943 |
60 |
Emory University | 1498 |
58 |
Hoffmann-La Roche Inc. | 3060 |
52 |
Centre National de La Recherche Scientifique | 9632 |
45 |
Novartis AG | 11238 |
42 |
The United States of America, as represented by the Secretary, Department of Health and Human Services | 2737 |
34 |
Janssen Sciences Ireland Unlimited Company | 431 |
33 |
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | 616 |
32 |
Katholieke Universiteit Leuven | 1035 |
31 |
Janssen Sciences Ireland UC | 256 |
28 |
The Johns Hopkins University | 5377 |
27 |
President and Fellows of Harvard College | 5792 |
27 |
Aicuris GmbH & Co. KG | 120 |
26 |
Institut National de La Sante et de La Recherche Medicale (inserm) | 2360 |
26 |
Merck Sharp & Dohme Corp. | 2247 |
25 |
The Board of Trustees of the Leland Stanford Junior University | 6054 |
23 |
Intervet International B.V. | 1235 |
23 |
Other owners | 6742 |